These studies highlight CD29's crucial role in the tumour microenvironment, suggesting its dual high expression in tumour and immune cells, providing a theoretical foundation for our study's mechanism by which Tregs upregulate CD29 to induce EMT and drive MASLD malignancy. The gene discussed is ITGB1; the disease is metabolic dysfunction-associated steatotic liver disease.